🟢 100/100

This product looks safe

  • No ingredients exceed tolerable upper intake levels
  • 38% of ingredients have research evidence
A Label Compliance Grade

Product Label

📸

Have a supplement label? Find it here.

Upload a photo of any supplement label to search our database of 92,312 products.

Label Data

1 Softgel(s) Serving Size
Other Combinations Product Type
38% Evidence Coverage

Supplement Facts — Evidence Check

Calories
11 Calorie(s)
Total Fat
1 Gram(s) (2% DV)
Cholesterol
Gamma-Linolenic Acid
100 mg
📊 Market median: 750.0mg (447 products) 📚 388 studies (Tier A: 18, B: 204)
This product: 500mg UL 3000mg
📊 Market median: 750.0mg (447 products) 📚 388 studies (Tier A: 18, B: 204)
This product: 300mg UL 3000mg
📊 Market median: 750.0mg (447 products) 📚 388 studies (Tier A: 18, B: 204)
This product: 200mg UL 3000mg
2.5 mg
📊 Market median: 4.0mg (47 products)
This product: 2.5mg

Other Ingredients

Gelatin Glycerin purified Water Lemon Oil extra virgin Olive Oil Mixed Tocopherols Citric Acid Ascorbyl Palmitate Rosemary extract

Label Claims — Verification

Nutrient
All Other
All Other (99% of products) Structure/Function (86% of products) Nutrient (79% of products) Qualified Health (13% of products) Approved Health (2% of products)

Target Groups

Adult (18 - 50 Years)

Product Information

⚠️ Warnings & Precautions

Contains fish: Alaska Pollock and/or Pacific Whiting, Shellfish: Krill.

🧪 Formulation Notes

Contains fish: Alaska Pollock and/or Pacific Whiting, Shellfish: Krill.

With AlaskOmega, Calamarine, Superba Krill Oil

Product Details

DSLD Entry Date 2019-09-24
Product Type Other Combinations
Form Softgel Capsule
Brand Primal Force
DSLD ID 206523
Data Updated 2026-04-11

Research Evidence

495 Research Sources
56 Avg Quality Score
222 Meta Analysis
104 Clinical Trial
72 Rct
69 Systematic Review
11 Guideline
5 Cochrane Review
5 Regulatory Source
3 Narrative Review
1 Openfda Safety
A Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Meta Analysis The Cochrane database of systematic reviews 2018
A Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Meta Analysis The Cochrane database of systematic reviews 2020
A Omega-3 fatty acid addition during pregnancy
Meta Analysis The Cochrane database of systematic reviews 2018
A Omega-3 fatty acids for depression in adults
Systematic Review The Cochrane database of systematic reviews 2021
A Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Meta Analysis The Cochrane database of systematic reviews 2018
A Non-immunosuppressive treatment for IgA nephropathy
Meta Analysis The Cochrane database of systematic reviews 2024
A Omega-3 fatty acid supplementation for depression in children and adolescents
Meta Analysis The Cochrane database of systematic reviews 2024
A Interventions for fatigue and weight loss in adults with advanced progressive illness
Meta Analysis The Cochrane database of systematic reviews 2012
A Motor control exercise for chronic non-specific low-back pain
Meta Analysis The Cochrane database of systematic reviews 2016
A Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease
Meta Analysis The Cochrane database of systematic reviews 2018
View all evidence for Omega 3 →

Compare Similar Products

View all Omega 3 products →